Shanghai Tianchen (600620.SH) forecasts a increase in profit, with an estimated net profit of 30 to 34 million yuan for the year 2024, representing a year-on-year growth of approximately 37.54% to 55.88%.
Tianchen Co., Ltd. (600620.SH) announced that the company is expected to achieve a net profit attributable to the listed company's shareholders in the 2024 fiscal year...
Shanghai Tianchen (600620.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of approximately 30-34 million yuan in the annual period of 2024, an increase of approximately 37.54% to 55.88% compared to the same period last year.
During the reporting period, the company generated related income from the disposal of subsidiary equity due to optimizing its industry structure, which was not present in the same period last year.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025